Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.111318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Jie Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Ferroptosis, Up-Regulation, Aspartic Acid, Cystathionine beta-Synthase. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Institute of Technology.
Abstract (Originalsprache)
Dysregulation of non-essential amino acids (NEAAs) contributes to metabolic dysfunction-associated fatty liver disease (MAFLD) progression. Aspartate (ASP), an NEAA serving as a critical precursor for purine, asparagine, and arginine biosynthesis, exhibits unexplored pathophysiological significance in MAFLD. Mass spectrometry profiling identified hepatic ASP as the sole NEAA consistently depleted in both human patients with MAFLD and animal models. Dietary or orally administered ASP supplementation in mice significantly improved insulin sensitivity, suppressed de novo lipogenesis, and enhanced mitochondrial respiration, collectively ameliorating diet-induced MAFLD. Integrative multi-omics analyses revealed that ASP activates the trans-sulfuration pathway through cystathionine β-synthase (CBS) upregulation in hepatocytes, thereby attenuating ferroptosis-evidenced by elevated glutathione and reduced lipid peroxidation. Crucially, pharmacological ferroptosis inhibition (liproxstatin-1) abolished ASP-mediated hepatic improvements, while CBS blockade completely abrogated ASP's therapeutic effects. These findings establish ASP as a novel ferroptosis inhibitor with therapeutic promise for MAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: zyyyych@zju.edu.cn.
Förderung
- Zhejiang Institute of Technology
Zitieren
APA
Zhang, J., Lin, S., Zhang, T., Son, X., & Yu, C. (2026). Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111318
Vancouver
Zhang J, Lin S, Zhang T, Son X, Yu C. Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111318
BibTeX
@article{Zhang2026,
author = {Zhang, Jie and Lin, Shihua and Zhang, Tiantian and Son, Xing and Yu, Chaohui},
title = {Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.111318}
}
EUVIMED